



Proceedings OF THE National Academy of Sciences OF THE UNITED STATES OF AMERICA

September 13, 1994

Volume 91, Number 19

pp. 8729–9196

Table of Contents

CONDENSED INFORMATION FOR CONTRIBUTORS

i

AUTHOR INDEX

ix–xii

Commentary

De novo design of β -sheet proteins

Michael H. Hecht

8729–8730

Reviews

The development of mitochondrial medicine

Rolf Luft

8731–8738

Mitochondrial DNA sequence variation in human evolution
and disease

Douglas C. Wallace

8739–8746

Paper from a Colloquium

Hepatitis viruses: Changing patterns of human
disease (Correction)

9195

Robert H. Purcell

Kinetic intermediates in the reactions between
peptides and proteins of major histocompatibility
complex class II

Craig Beeson and Harden M. McConnell

8842–8845

Convenient separation of high-purity C_{60} from crude
fullerene extract by selective complexation with $AlCl_3$,
Imre Bucsi, Robert Anisfeld, Tatyana Shamma,
G. K. Surya Prakash, and George A. Olah

9019–9021

Physical Sciences

CHEMISTRY

Photolabile precursors of glutamate: Synthesis,
photochemical properties, and activation of
glutamate receptors on a microsecond time scale

8752–8756

Raymond Wieboldt, Kyle R. Gee, Li Niu,
Doraiswamy Ramesh, Barry K. Carpenter, and
George P. Hess

Biological Sciences

BIOCHEMISTRY

Betadoublet: *De novo* design, synthesis, and
characterization of a β -sandwich protein

8747–8751

Thomas P. Quinn, Neil B. Tweedy, Robert W.
Williams, Jane S. Richardson, and David C.
Richardson

Contents

| | | | |
|--|-----------|---|-----------|
| CCAAT/enhancer binding protein α is sufficient to initiate the 3T3-L1 adipocyte differentiation program Fang-Tsyr Lin and M. Daniel Lane | 8757–8761 | Enhancer 1 binding factor (E ₁ BF), a Ku-related protein, is a growth-regulated RNA polymerase I transcription factor: Association of a repressor activity with purified E ₁ BF from serum-deprived cells Hufeng Niu and Samson T. Jacob | 9101–9105 |
| Regulation of scallop myosin by the regulatory light chain depends on a single glycine residue Agnes Jancso and Andrew G. Szent-Györgyi | 8762–8766 | The transcription factor TFIIS zinc ribbon dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by RNA polymerase II ChoonJu Jeon, HoSup Yoon, and Kan Agarwal | 9106–9110 |
| RNA-dependent RNA polymerase from plants infected with turnip crinkle virus can transcribe (+) and (−)-strands of virus-associated RNAs Chuanzheng Song and Anne E. Simon | 8792–8796 | The phosphatidylinositol 3-kinase α is required for DNA synthesis induced by some, but not all, growth factors Serge Roche, Manfred Koegl, and Sara A. Courtneidge | 9185–9189 |
| Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53 Martin Scheffner, Jon M. Huibregtse, and Peter M. Howley | 8797–8801 | Polyamines regulate the expression of ornithine decarboxylase antizyme <i>in vitro</i> by inducing ribosomal frame-shifting (Correction) Eran Rom and Chaim Kahana | 9195 |
| Induction of structural changes in the bovine papillomavirus type 1 origin of replication by the viral E1 and E2 proteins Thomas G. Gillette, Monika Lusky, and James A. Borowiec | 8846–8850 | Assembly of synthetic cellulose I (Correction) Jong H. Lee, R. Malcolm Brown, Jr., Shigenori Kuga, Shin-ichiro Shoda, and Shiro Kobayashi | 9195 |
| The bovine papillomavirus E2 protein modulates the assembly of but is not stably maintained in a replication-competent multimeric E1–replication origin complex Monika Lusky, Jerard Hurwitz, and Yeon-Soo Seo | 8895–8899 | BIOPHYSICS | |
| Antizyme protects against abnormal accumulation and toxicity of polyamines in ornithine decarboxylase-overproducing cells Toshikazu Suzuki, Yong He, Keiko Kashiwagi, Yasuko Murakami, Shin-ichi Hayashi, and Kazuei Igarashi | 8930–8934 | The structure of a complex of hexameric insulin and 4'-hydroxyacetanilide G. David Smith and Ewa Ciszak | 8851–8855 |
| Constitutive activation of Mek1 by mutation of serine phosphorylation sites Weidong Huang and Raymond L. Erikson | 8960–8963 | Synergy in the spectral tuning of retinal pigments: Complete accounting of the opsin shift in bacteriorhodopsin Jingui Hu, Robert G. Griffin, and Judith Herzfeld | 8880–8884 |
| Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution Hiroshi Sakamoto, Marc S. Lewis, Hiroaki Kodama, Ettore Appella, and Kazuyasu Sakaguchi | 8974–8978 | Femtosecond photodichroism studies of isolated photosystem II reaction centers Gary P. Wiederrecht, Michael Seibert, Govindjee, and Michael R. Wasielewski | 8999–9003 |
| Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to <i>Escherichia coli</i> enterotoxin B subunit Alessandro Marcello, Arianna Loreanian, Anne Cross, Howard Marsden, Timothy R. Hirst, and Giorgio Palù | 8994–8998 | Computation with chaos: A paradigm for cortical activity A. Babloyantz and C. Lourenço | 9027–9031 |
| An <i>in vitro</i> polysome display system for identifying ligands from very large peptide libraries Larry C. Mattheakis, Ramesh R. Bhatt, and William J. Dower | 9022–9026 | CELL BIOLOGY | |
| Involvement of the C-terminal residues of the 20,000-dalton light chain of myosin on the regulation of smooth muscle actomyosin Mitsuo Ikebe, Sheila Reardon, Yasuo Mitani, Hiroshi Kamisoyama, Motoi Matsuura, and Reiko Ikebe | 9096–9100 | P-selectin induces the expression of tissue factor on monocytes Alessandro Celi, Giuliana Pellegrini, Roberto Lorenzetti, Antonio De Blasi, Neal Ready, Barbara C. Furie, and Bruce Furie | 8767–8771 |
| | | Integrin $\alpha_5\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen Anthony M. P. Montgomery, Ralph A. Reisfeld, and David A. Cheresh | 8856–8860 |
| | | Stringent sequence requirements for the formation of human telomeres John P. Hanish, Judith L. Yanowitz, and Titia de Lange | 8861–8865 |
| | | Activated Ki-Ras complements erythropoietin signaling in CTLL-2 cells, inducing tyrosine phosphorylation of a 160-kDa protein Yasuko Yamamura, Makoto Noda, and Yoji Ikawa | 8866–8870 |

Contents

| | | | |
|---|-----------|---|-----------|
| Subcellular localization of the UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-mediated O-glycosylation reaction in the submaxillary gland Jürgen Roth, Yang Wang, Allen E. Eckhardt, and Robert L. Hill | 8935–8939 | Evidence for multiple competitive peaks from populations of bacteria evolving in a structured habitat Ryszard Korona, Cindy H. Nakatsu, Larry J. Forney, and Richard E. Lenski | 9037–9041 |
| Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein Yuqiao Shen and Thomas Shenk | 8940–8944 | | |
| Direct observation of substance P-induced internalization of neurokinin 1 (NK ₁) receptors at sites of inflammation Jeffrey J. Bowden, Adella M. Garland, Peter Baluk, Peter Lefevre, Eileen F. Grady, Steven R. Vigna, Nigel W. Bunnett, and Donald M. McDonald | 8964–8968 | | |
| Long-term culture and functional characterization of follicular cells from adult normal human thyroids Francesco Curcio, Francesco Saverio Ambesi-Impiombato, Giuseppina Perrella, and Hayden G. Coon | 9004–9008 | A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype Gabriele Aquilina, Patricia Hess, Pauline Branch, Catriona MacGeoch, Ida Casciano, Peter Karran, and Margherita Bignami | 8905–8909 |
| Two yeast genes with similarity to TCP-1 are required for microtubule and actin function <i>in vivo</i> Xiaoyue Chen, Donald S. Sullivan, and Tim C. Huffaker | 9111–9115 | A targeted chain-termination mutation in the mouse <i>Apc</i> gene results in multiple intestinal tumors Riccardo Fodde, Winfried Edelmann, Kan Yang, Claus van Leeuwen, Christine Carlson, Beatrice Renault, Cor Breukel, Elaine Alt, Martin Lipkin, P. Meera Khan, and Raju Kucherlapati | 8969–8973 |
| A yeast TCP-1-like protein is required for actin function <i>in vivo</i> Dani Bich-Nga Vinh and David G. Drubin | 9116–9120 | Early myeloid cell-specific expression of the human cathepsin G gene in transgenic mice Jay L. Grisolano, Gary M. Sclar, and Timothy J. Ley | 8989–8993 |
| Identification of soluble forms of the fibroblast growth factor receptor in blood Anne Hanneken, Wenbin Ying, Nicholas Ling, and Andrew Baird | 9170–9174 | A transposable element can drive the concerted evolution of tandemly repetitive DNA Dianne Thompson-Stewart, Gary H. Karpen, and Allan C. Spradling | 9042–9046 |
| Mapping of the C5a receptor signal transduction network in human neutrophils Anne Mette Buhl, Natalie Avdi, G. Scott Worthen, and Gary L. Johnson | 9190–9194 | DNA polymerase δ is required for base excision repair of DNA methylation damage in <i>Saccharomyces cerevisiae</i> A. Blank, Baek Kim, and Lawrence A. Loeb | 9047–9051 |
| DEVELOPMENTAL BIOLOGY | | | |
| The cellular retinoic acid binding protein I is dispensable Philippe Gorry, Thomas Lufkin, Andrée Dierich, Cécile Rochette-Egly, Didier Décimo, Pascal Dollé, Manuel Mark, Béatrice Durand, and Pierre Chambon | 9032–9036 | Genetic variation detected by quantitative analysis of end-labeled genomic DNA fragments Jun-ichi Asakawa, Rork Kuick, James V. Neel, Mieko Kodaira, Chiyoko Satoh, and Samir M. Hanash | 9052–9056 |
| ECOLOGY | | | |
| Eastern Pacific molluscan provinces and latitudinal diversity gradient: No evidence for "Rapoport's rule" Kaustuv Roy, David Jablonski, and James W. Valentine | 8871–8874 | Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein Karen K. Hsiao, Darlene Groth, Michael Scott, Shu-Lian Yang, Hana Serban, Dennis Rapp, Dallas Foster, Marilyn Torchia, Stephen J. DeArmond, and Stanley B. Prusiner | 9126–9130 |
| EVOLUTION | | | |
| Gene trees and hominoid phylogeny Maryellen Ruvolo, Deborah Pan, Sarah Zehr, Tony Goldberg, Todd R. Disotell, and Miranda von Dornum | 8900–8904 | IMMUNOLOGY | |
| | | Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy Mikael Dahlsten, Lars Abrahamson, Per Björk, Peter A. Lando, Gunnar Hedlund, Göran Forsberg, Thomas Brodin, Nick R. J. Gascoigne, Cecilia Förberg, Peter Lind, and Terje Kalland | 8945–8949 |
| | | Binding of soluble natural ligands to a soluble human T-cell receptor fragment produced in <i>Escherichia coli</i> Katherine L. Hilyard, Hugh Reyburn, Shan Chung, John I. Bell, and Jack L. Strominger | 9057–9061 |

Contents

| | | | |
|---|-----------|---|-----------|
| Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: Localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia | 9062–9066 | A murine model for B-lymphocyte somatic cell gene therapy | 8875–8879 |
| Yuko Ohta, Robert N. Haire, Ronda T. Litman, Shu Man Fu, Robert P. Nelson, Jamie Kratz, Stephen J. Kornfeld, Maite de la Morena, Robert A. Good, and Gary W. Litman | | Natalie Sutkowski, Ming-Ling Kuo, Alfredo Varela-Echavarria, Joseph P. Dougherty, and Yacov Ron | |
| BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity | 9136–9140 | BCL2 translocation frequency rises with age in humans | 8910–8914 |
| A. Bensussan, E. Gluckman, S. El Marsafy, V. Schiavon, I.-G. Mansur, J. Dausset, L. Boumsell, and E. Carosella | | Yafei Liu, Antonio M. Hernandez, Darryl Shibata, and Gino A. Cottopass | |
| Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse | 9146–9150 | Adeno-associated virus vectors preferentially transduce cells in S phase | 8915–8919 |
| Allan G. Murray, Peter Petzelbauer, Christopher C. W. Hughes, José Costa, Philip Askenase, and Jordan S. Pober | | David W. Russell, A. Dusty Miller, and Ian E. Alexander | |
| The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C | 9175–9179 | Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells | 9009–9013 |
| Libo Yao, Yuko Kawakami, and Toshiaki Kawakami | | Tetsuya Ueba, Tetsuya Nosaka, Jun A. Takahashi, Futoshi Shibata, Robert Z. Florkiewicz, Bert Vogelstein, Yoshifumi Oda, Haruhiko Kikuchi, and Masakazu Hatanaka | |
| The $\alpha 3$ chain of type IV collagen induces autoimmune Goodpasture syndrome (Correction) | 9195 | A lag in intracellular degradation of mutant α_1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ α_1-antitrypsin deficiency | 9014–9018 |
| Raghuram Kalluri, Vincent H. Gattone II, Milton E. Noelken, and Billy G. Hudson | | Ying Wu, Ina Whitman, Ernesto Molmenti, Kenneth Moore, Paul Hippenmeyer, and David H. Perlmutter | |
| MEDICAL SCIENCES | | | |
| Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-β | 8772–8776 | Direct isolation of genes encoded within a homogeneously staining region by chromosome microdissection | 9121–9125 |
| Keunchil Park, Seong-Jin Kim, Yung-Jue Bang, Jae-Gabb Park, Noe Kyong Kim, Anita B. Roberts, and Michael B. Sporn | | Yan A. Su, Jeffrey M. Trent, Xin-Yan Guan, and Paul S. Meltzer | |
| An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3 | 8802–8806 | Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein | 9131–9135 |
| Andrew J. Bett, Wael Haddara, Ludvik Prevec, and Frank L. Graham | | Shosuke Imai, Shigeki Koizumi, Makoto Sugiura, Masayoshi Tokunaga, Yoshiko Uemura, Noriko Yamamoto, Sadao Tanaka, Eiichi Sato, and Toyoro Osato | |
| Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins | 8807–8811 | Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice | 9141–9145 |
| Ann Marie Schmidt, Mirela Hasu, Doina Popov, Jing Hua Zhang, Jingxian Chen, Shi Du Yan, Jerold Brett, Rong Cao, Keisuke Kuwabara, Gabriela Costache, Nicolae Simionescu, Maya Simionescu, and David Stern | | Nancy E. Kohl, Francine R. Wilson, Scott D. Mosser, Elizabeth Giuliani, S. Jane deSolms, Michael W. Conner, Neville J. Anthony, Wilbur J. Holtz, Robert P. Gomez, Ta-Jyh Lee, Robert L. Smith, Samuel L. Graham, George D. Hartman, Jackson B. Gibbs, and Allen Oliff | |
| The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump | 8822–8826 | Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus | 9151–9154 |
| G. J. R. Zaman, M. J. Flens, M. R. van Leusden, M. de Haas, H. S. Mulder, J. Lankelma, H. M. Pinedo, R. J. Scheper, F. Baas, H. J. Broxterman, and P. Borst | | Alfons Valera, Anna Pujol, Mireia Pelegrin, and Fatima Bosch | |
| Evidence that the vectorial competence of phlebotomine sand flies for different species of <i>Leishmania</i> is controlled by structural polymorphisms in the surface lipophosphoglycan | 9155–9159 | | |
| | | Paulo F. P. Pimenta, Elvira M. B. Saraiva, Edgar Rowton, Govind B. Modi, Levi A. Garraway, Stephen M. Beverley, Salvatore J. Turco, and David L. Sacks | |

Contents

MICROBIOLOGY

- Interaction between the aphid transmission factor and virus particles is a part of the molecular mechanism of cauliflower mosaic virus aphid transmission
Isabelle Schmidt, Stéphane Blanc, Pascal Esperandieu, Georges Kuhl, Gérard Devauchelle, Claude Louis, and Martine Cerutti

8885-8889

Microglia in intact ganglia

- Dario Sonetti, Enzo Ottaviani, Francesca Bianchi, Madeline Rodriguez, Michelle L. Stefano, Berta Scharrer, and George B. Stefano

9180-9184

- Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in *Escherichia coli*
Duk-Ju Hwang, Ian M. Roberts, and T. Michael A. Wilson

9067-9071

PHARMACOLOGY

- Cellular signaling by an agonist-activated receptor/G_a fusion protein

- Brigitte Bertin, Michael Freissmuth, Ralf Jockers, A. Donny Strosberg, and Stefano Marullo

8827-8831

NEUROBIOLOGY

- Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary
E. Potter, S. Sutton, C. Donaldson, R. Chen, M. Perrin, K. Lewis, P. E. Sawchenko, and W. Vale
- Murine oligodendroglial cells express nerve growth factor
Sujatha Byravan, Lyndon M. Foster, Tommy Phan, A. Neil Verity, and Anthony T. Campagnoni

8777-8781

8812-8816

- Heteromeric olfactory cyclic nucleotide-gated channels: A subunit that confers increased sensitivity to cAMP
Jonathan Bradley, Jun Li, Norman Davidson, Henry A. Lester, and Kai Zinn
- Brain-derived neurotrophic factor increases the electrical activity of pars compacta dopamine neurons *in vivo*
Roh-Yu Shen, C. Anthony Altar, and Louis A. Chiodo

8890-8894

8920-8924

- Cyanotriphenylborate: Subtype-specific blocker of glycine receptor chloride channels
Nils Rundström, Volker Schmieden, Heinrich Betz, Joachim Bormann, and Dieter Langosch
- Reproenkephalin promoter yields region-specific and long-term expression in adult brain after direct *in vivo* gene transfer via a defective herpes simplex viral vector
Michael G. Kaplitt, Ann D. Kwong, Steven P. Kleopoulos, Charles V. Mobbs, Samuel D. Rabkin, and Donald W. Pfaff

8950-8954

8979-8983

- Transgenic engineering of neuromuscular junctions in *Xenopus laevis* embryos transiently overexpressing key cholinergic proteins
Michael Shapira, Shlomo Seidman, Meira Sternfeld, Rina Timberg, Daniela Kaufer, James Patrick, and Hermona Soreq

9072-9076

- Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease
Jeffrey H. Kordower, Vinod Charles, Robert Bayer, Raymond T. Bartus, Scott Putney, Lee R. Walus, and Phillip M. Friden

9077-9080

- Genomic structure and analysis of promoter sequence of a mouse μ opioid receptor gene
Bon H. Min, Lance B. Augustin, Roderick F. Felsheim, James A. Fuchs, and Horace H. Loh

- Regulation of receptor internalization by the major histocompatibility complex class I molecule
Lennart Olsson, Avram Goldstein, and Jan Stagsted

9081-9085

9086-9090

PHYSIOLOGY

- On measuring the third dimension of cultured endothelial cells in shear flow

- S. Q. Liu, Morris Yen, and Y. C. Fung

8782-8786

- ω 3 polyunsaturated fatty acid modulates dihydropyridine effects on L-type Ca^{2+} channels, cytosolic Ca^{2+} , and contraction in adult rat cardiac myocytes
Salvatore Pepe, Konstantin Bogdanov, Haifa Hallaq, Harold Spurgeon, Alexander Leaf, and Edward Lakatta

8832-8836

- Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat
Susan R. DiGiovanni, Søren Nielsen, Erik Iisø Christensen, and Mark A. Knepper

8984-8988

- Creatine kinase (CK) in skeletal muscle energy metabolism: A study of mouse mutants with graded reduction in muscle CK expression
Jan van Deursen, Wim Ruitenberg, Arend Heerschap, Paul Jap, Henk ter Laak, and Bé Wieringa

9091-9095

- Phosphatase inhibitors activate normal and defective CFTR chloride channels

- Frédéric Becq, Timothy J. Jensen, Xiu-Bao Chang, Anna Savoia, Johanna M. Rommens, Lap-Chee Tsui, Manuel Buchwald, John R. Riordan, and John W. Hanrahan

9160-9164

- Involvement of microtubules in the link between cell volume and pH of acidic cellular compartments in rat and human hepatocytes

- Gillian L. Busch, Rainer Schreiber, Peter C. Dartsch, Harald Völk, Stephan vom Dahl, Dieter Häussinger, and Florian Lang

9165-9169

Contents

PLANT BIOLOGY

| | | | |
|--|-----------|--|-----------|
| The recovery of photosynthesis from low-temperature photoinhibition is accelerated by the unsaturation of membrane lipids: A mechanism of chilling tolerance Zoltan Gombos, Hajime Wada, and Norio Murata | 8787-8791 | An ethylene-responsive enhancer element is involved in the senescence-related expression of the carnation glutathione-S-transferase (<i>GST1</i>) gene Hanan Itzhaki, Julie M. Maxson, and William R. Woodson | 8925-8929 |
| Cloning and characterization of a maize pollen-specific calcium-dependent calmodulin-independent protein kinase Juan J. Estruch, Sue Kadwell, Ellis Merlin, and Lyle Crossland | 8837-8841 | Isolation of phytoalexin-deficient mutants of <i>Arabidopsis thaliana</i> and characterization of their interactions with bacterial pathogens Jane Glazebrook and Frederick M. Ausubel | 8955-8959 |

Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins

(glycated protein/endothelium/receptor/diabetes mellitus)

ANNE MARIE SCHMIDT^{*†}, MIRELA HASU[‡], DOINA POPOV[‡], JING HUA ZHANG[§], JINGXIAN CHEN[§], SHI DU YAN[§], JEROLD BRETT[§], RONG CAO[§], KEISUKE KUWABARA[§], GABRIELA COSTACHE[‡], NICOLAE SIMIONESCU[‡], MAYA SIMIONESCU[‡], AND DAVID STERN[§]

Departments of *Medicine and [†]Physiology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032; and [‡]Institute of Cellular Biology and Pathology, 8 B.P. Hasdeu Street, Bucharest-79691, Romania

Communicated by George E. Palade, April 7, 1994

ABSTRACT The extended interaction of aldoses with proteins or lipids results in nonenzymatic glycation and oxidation, ultimately forming AGEs, the presence of which in the plasma and vessel wall is associated with diabetic vascular complications. We show here that AGE albumin in the intravascular space interacts with the vessel wall via binding to an integral membrane protein, receptor for AGE (RAGE), a member of the immunoglobulin superfamily, resulting in clearance from the plasma and induction of interleukin 6 mRNA. Intravenously infused ¹²⁵I-AGE albumin showed a rapid phase of plasma clearance with deposition in several organs. Rapid removal of ¹²⁵I-AGE albumin from the plasma was prevented by administration of a soluble, truncated form of RAGE, which blocked binding of ¹²⁵I-labeled AGE albumin to cultured endothelial cells and mononuclear phagocytes, as well as by pretreatment with anti-RAGE IgG. Ultrastructural studies with AGE albumin–colloidal gold conjugates perfused *in situ* showed that in murine coronary vasculature this probe was taken up by endothelial plasmalemmal vesicles followed by transport either to the abluminal surface or by accumulation in intracellular vesicular structures reminiscent of endosomes and lysosomes. Consequences of AGE–RAGE interaction included induction of interleukin 6 mRNA expression in mice. These data indicate that RAGE mediates the interaction of AGEs with the vessel wall, both for removal of these glycated proteins from the plasma and for changes in gene expression.

When proteins or lipids are exposed to aldoses, they undergo nonenzymatic glycation and oxidation (1–8), ultimately forming AGEs, whose formation occurs during normal aging and is accelerated in diabetics (1–7). The presence of AGEs in the plasma and vessel wall has been linked to the pathogenesis of diabetic complications, stimulating investigations to determine mechanisms through which AGEs exert their pathologic effects.

An important mechanism through which AGEs interact with cells is through specific receptors (9–13). We thus evaluated the role of the receptor for AGE (RAGE), which specifically binds AGEs (10–12), in mediating the interactions of these glycated molecules with target cells such as endothelial cells (ECs) and mononuclear phagocytes (MPs) (10, 11, 13). Previous studies have identified the presence of RAGE in bovine cardiac vasculature (13). We have now identified RAGE in murine coronary vasculature both *in vivo* and *in vitro* and employed this model to demonstrate that RAGE has a central role in uptake by the endothelium and in gene expression following AGE infusion.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

MATERIALS AND METHODS

Preparation of AGE Albumin, RAGE, and Anti-RAGE Antibody. Mouse and bovine AGE albumin were prepared and characterized as described (2, 10, 11). Radiolabeling of AGE and native albumin was performed by the lactoperoxidase method (14); the tracers had specific radioactivities of $\approx 1.5 \times 10^4$ cpm/ng (10, 11). For AGE albumin–gold conjugates, colloidal gold particles (5 nm in diameter) were prepared as described (15, 16). Bovine RAGE and monospecific rabbit anti-RAGE IgG were prepared and characterized as described (11). The ≈ 35 -kDa form of bovine RAGE was termed soluble RAGE (sRAGE; refs. 10 and 12).

Cell Binding Assays. Binding of ¹²⁵I-AGE albumin to cultured bovine adrenal capillary ECs or human MPs was studied as described (10, 11, 17).

Infusion/Uptake Studies. ¹²⁵I-labeled AGE albumin or ¹²⁵I-labeled native albumin ($\approx 3 \mu\text{g}$) was infused via the tail vein of CD₁ mice with or without preincubation with a 50-fold molar excess of sRAGE or preinfusion of the animals with either anti-RAGE IgG or nonimmune IgG. To assess tissue deposition, organs were removed and the weight and radioactivity (cpm) were measured (18). The method of Spady *et al.* (19) was used to calculate the tissue spaces. To correct for nonspecific tissue trapping of tracer, a tissue space for ¹²⁵I-albumin was calculated (18). All preparations of proteins utilized in infusion studies were tested in the *Limulus amebocyte assay* (Sigma) for lipopolysaccharide content and, where indicated, were chromatographed on Detoxi-Gel columns (Pierce). Inactive heat-treated AGE albumin (boiled for 15 min) was also employed.

Effect of AGE Albumin Infusion on Levels of Interleukin 6 (IL-6) Transcripts. Three hours after AGE albumin infusion, mice were sacrificed, livers were excised, total RNA was extracted, and poly(A)⁺ mRNA was prepared (20, 21). Random hexanucleotide-primed first-strand cDNA served as the template for polymerase chain reaction (PCR) analysis. Murine IL-6 primers and actin primers were obtained from Clontech. cDNA for murine IL-6 was amplified by PCR for 35 cycles, each consisting of incubations at 94°C for 2 min (first cycle) or 45 sec (remaining 34 cycles), 60°C for 45 sec, and 72°C for 2 min followed by 7 min at 72°C linked to 4°C. A similar protocol was utilized for the β -actin primers except that 25 cycles were employed. Products were separated by 2% agarose gel electrophoresis and transferred to nylon membrane for Southern hybridization with a ³²P-labeled oligonucleotide probe for murine IL-6 (Clontech).

Abbreviations: AGE, advanced glycation end product; RAGE, receptor for AGE; sRAGE, soluble RAGE; EC, endothelial cell; MP, mononuclear phagocyte; IL, interleukin.

^{*}To whom reprint requests should be addressed.




FIG. 1. (Legend appears at the bottom of the opposite page.)

Ultrastructural Studies of Vessel Uptake of AGE Albumin. Via laparotomy, mice were catheterized, and the vasculature was washed free of blood with phosphate-buffered saline (PBS) containing albumin (3.5 mg/ml) by using the vena cava as the outflow track. AGE albumin conjugated to colloidal gold was introduced at a flow rate of 3 ml/min at 37°C for 4 or 15 min. Unbound ligand was removed by perfusing PBS (3 min; 3 ml/min) and then 2.5% formaldehyde/1.5% glutaraldehyde/2.5 mM CaCl₂/0.1 M sodium cacodylate-HCl buffer (pH 7.2). Thin sections of myocardium were cut on an OmU Reichert Ultramicrotome, stained with uranyl acetate and lead citrate, and examined with a Philips 400 HM electron microscope.

Identification of Murine RAGE Antigen and mRNA in Cardiac Vasculature and Cultured Murine Coronary ECs. RAGE was detected immunohistochemically on freshly harvested mouse cardiac tissue fixed overnight with 3.5% formalin in PBS and on confluent cultured murine coronary ECs (generously provided by R. Auerbach, University of Wisconsin, Madison) fixed in buffered 3.5% paraformaldehyde. After preparation, immunostaining with anti-RAGE IgG was performed as described (13). *In situ* hybridization was performed with digoxigenin-labeled RNA probes (13). Immunoblotting was performed with 10⁷ cultured murine coronary ECs (10, 11, 13, 22).

RESULTS

AGE Expression in Murine Cardiac Vasculature. Immunohistochemistry demonstrated the presence of RAGE in murine coronary vessels, compared with absence of staining with nonimmune IgG, and *in situ* hybridization confirmed the presence of the mRNA with antisense probe, whereas sense controls were negative (data not shown). Experiments were also performed with cultured murine coronary ECs: RAGE was evident in nonpermeabilized samples, and *in situ* hybridization demonstrated RAGE mRNA (data not shown). Consistent with these results, Western blotting of detergent extracts of cultured murine coronary ECs demonstrated the presence of a single band at ≈35 kDa which was specifically immunoreactive with anti-RAGE IgG.

Effect of sRAGE and Anti-RAGE IgG on the Binding of AGE Albumin to Cultured ECs and MPs and on the Removal of Infused AGE Albumin from the Blood. To analyze the contribution of RAGE in the interaction of AGEs with cellular elements, we employed monospecific polyclonal anti-RAGE IgG which blocks the interaction of AGEs with cultured ECs and MPs (10, 11), and sRAGE. Addition of sRAGE to incubation mixtures of ¹²⁵I-labeled AGE albumin with either ECs or MPs resulted in dose-dependent inhibition of binding (Fig. 1A). sRAGE did not affect binding of ¹²⁵I-labeled factor IX to cultured ECs (data not shown).

To determine the role of RAGE in the handling of circulating AGEs, infusion studies were performed with ¹²⁵I-labeled AGE or native albumin in mice (Fig. 1B). ¹²⁵I-labeled AGE albumin showed an initial rapid phase of removal from the blood, with ≈70% of the material gone by 5 min (Fig. 1B Left). The deposition of ¹²⁵I-AGE albumin in the tissues, studied just after the rapid phase of AGE clearance from the blood, was enhanced relative to that of ¹²⁵I-albumin, especially in the liver, lung, and kidney (Fig. 1B Right). When ¹²⁵I-AGE albumin was preincubated with sRAGE and infused into mice (Fig. 1C), the rapid phase of tracer clearance was largely blocked; sRAGE had no effect on ¹²⁵I-albumin plasma levels (Fig. 1C Left). Animals pretreated with anti-RAGE IgG showed an even more complete blockade of the early clearance phase of infused ¹²⁵I-AGE albumin. The clearance of ¹²⁵I-albumin was again unaffected (data not shown). Nonimmune IgG had no effect (Fig. 1D Left). Administration of ¹²⁵I-AGE albumin with sRAGE or pretreatment with anti-RAGE IgG prior to ¹²⁵I-AGE albumin infusion strikingly decreased its deposition in the organs (Figs. 1C Right and D Right, respectively), suggesting that AGE albumin is initially cleared from the circulation and deposited in the organs/vasculature via a process which involves RAGE.

Ultrastructural Studies of AGE Albumin with the Vessel Wall. To assess vessel wall processing of infused AGEs, morphologic studies were performed with AGE albumin conjugated to colloidal gold particles, employing murine cardiac vasculature as a model system (23, 24). Four minutes after *in situ* perfusion, AGE albumin-gold conjugates decorated numerous plasmalemmal vesicles opened to the luminal front (Fig. 2A), while coated pits and coated vesicles were unlabeled (Fig. 2B). However, multivesicular bodies (Fig. 2B) and structures resembling endosomes appeared significantly decorated by the tracer (Fig. 2C and D). Gold particles were also seen in the proximity of the abluminal endothelial cell surface (Fig. 2D). Sparse gold particles were occasionally observed in the subendothelial space (Fig. 2A and D), suggesting that transcytosis had occurred. At 15 min, the presence of AGE albumin-gold particles in the subendothelial space was even more apparent. These experiments were performed in the presence of a large excess of native albumin (3.5 mg/ml) to block the interaction of determinants on albumin with vessel wall albumin-binding proteins (24–27). In addition, the presence of excess free AGE albumin blocked association of AGE albumin-gold particles with the heart tissue by >50%, while anti-RAGE IgG prevented such association by 50–70%. Similar results were observed in studies using ¹²⁵I-AGE albumin (data not shown).

Infusion of AGE Albumin Leads to Induction of IL-6 mRNA: Effect of Anti-RAGE IgG. AGEs have been reported to modulate cell properties *in vitro*, including the induction of genes for cytokines and growth factors (28, 29). In view of the

FIG. 1. Intravascular perfusion of ¹²⁵I-AGE albumin and ¹²⁵I-albumin into mice: Effect of sRAGE and anti-RAGE IgG. (A) Effect of sRAGE on the binding of ¹²⁵I-AGE albumin to cultured ECs (Left) and MPs (Right). (Left) Confluent bovine adrenal capillary ECs were incubated with ¹²⁵I-AGE albumin (100 nM) either alone (total binding), in the presence of a 30-fold excess of unlabeled AGE albumin (nonspecific binding), or with the indicated molar excess of sRAGE for 3 hr at 4°C. Percent maximal specific binding (total minus nonspecific binding), mean ± SEM of triplicate determinations, is shown. Maximal binding was ≈10 fmol per well. (Right) Cultured human MPs (5 × 10⁴ per well) were tested for their capacity to bind ¹²⁵I-AGE albumin (100 nM) as in A Left. Maximal binding with MPs was ≈6 fmol per well. (B Left) Removal of ¹²⁵I-AGE albumin and ¹²⁵I-native albumin from the plasma. Mice were infused with tracer (3 µg per animal), and blood was withdrawn for determination of radioactivity. The mean ± SEM is shown, and experiments were repeated at least three times. (B Right) Deposition of infused ¹²⁵I-labeled AGE albumin (▲) or ¹²⁵I-labeled native albumin (●). Mice were infused as in B Left and after 10 min radioactivity in the tissues was determined. Results in mice treated with ¹²⁵I-AGE albumin were compared with those in animals exposed to ¹²⁵I-native albumin, and the mean ± SEM is shown. (C) Effect of sRAGE on ¹²⁵I-AGE albumin clearance from the plasma (Left) and deposition in the tissues (Right). The same experiment as in B was performed, but both ¹²⁵I-AGE albumin (▲, △) and ¹²⁵I-albumin (●, ○) were preincubated for 60 min at 37°C with (Δ, ○, open bars) or without (▲, ●, filled bars) a 50-fold molar excess of sRAGE. (D) Effect of anti-(α)-RAGE IgG on ¹²⁵I-AGE albumin clearance from the plasma (Left) and deposition in the tissues (Right). The same experiment as in B was performed, but animals were pretreated for 30 min with either anti-RAGE IgG or nonimmune (NI) IgG (40 µg per animal). ▲ and filled bars, ¹²⁵I-AGE albumin; □ and open bars, ¹²⁵I-AGE plus anti-RAGE IgG; Δ, ¹²⁵I-AGE albumin plus nonimmune IgG; ○, ¹²⁵I-albumin. In all cases representative experiments are shown. Approximately 50 mice were employed for each experimental condition.




FIG. 2. Interaction of AGE albumin-gold conjugates with myocardial capillary endothelium at 4 min (*A–C*) and 15 min (*D–F*) after tracer perfusion *in situ*. (*A*) The particles are preferentially taken up by plasmalemmal vesicles (*v*), open to the luminal front, whereas coated pits (*cpi*) are not labeled by the tracer. (*B*) The probe is endocytosed in a multivesicular body (*mv*). The intercellular junction (*j*) is not permeated by the tracer. (*C*) Large vesicles (*e*) (most likely of the endosomal compartment) are decorated. (*D*) At 15 min, almost every vesicle associated with the abluminal front (*av*) appears as discharging its contents into the subendothelial space (arrow). (*E*) In this segment, almost every vesicle associated with the abluminal front (*av*) appears as discharging its contents into the subendothelial space (arrow). At *j*, an intercellular junction containing tracer in its luminal infundibulum (arrowhead) is observed. (*F*) In some areas, the complex (arrow) has reached the subendothelial extracellular compartment. *l*, Lumen; *ss*, subendothelial space; *bl*, basal lamina. ($\times 75,000$.)

association of diabetes with increased levels of fibrinogen, an important risk factor for vascular complications (30–32), the ability of infused AGE albumin to elevate mRNA levels of IL-6, a cytokine linked to fibrinogen synthesis (33–35), was studied. Infusion of AGE albumin into normal mice led to an increase in IL-6 transcripts, compared with control animals infused with native albumin (Fig. 3*A*, lanes 3 and 2, respectively). The migration of the PCR band amplified from AGE albumin-treated mice was identical to that induced by exposure of animals to bacterial lipopolysaccharide, a known inducer of IL-6 (33) (Fig. 3*A*, lane 6). Southern blotting of these PCR products with an oligonucleotide probe for murine IL-6 confirmed the identity of the above amplicons (Fig. 3*B*, lanes 3 and 6, respectively). The increase in IL-6 transcripts in response to AGE albumin was blocked by pretreatment of mice with anti-RAGE IgG, whereas nonimmune IgG was without effect (Fig. 3*A* and *B*, lanes 4 and 5, respectively). Heat treatment of these preparations abrogated their ability to induce IL-6 (data not shown).

DISCUSSION

Our data indicate that AGE albumin present in the intravascular space interacts with endothelial RAGE, resulting in its

removal from the plasma and subsequent endocytosis and transcytosis. Cell-bound AGEs can modulate cellular properties, as occurs after AGE-mediated activation of transcription factor NF- κ B (36), generation of tumor necrosis factor and IL-1 (28), and induction of IL-6 mRNA (37). In addition, some of the AGE albumin is transferred across the endothelium by transcytosis, depositing ligand in the subendothelium where AGEs can potentially form crosslinks altering basement membrane structure and function (2), as well as interacting with other cells in the subendothelial space that bear RAGE. Subsequently, recruitment of intracellular second-messenger pathways and effector mechanisms in response to AGE engagement of RAGE could be initiated by signals in the cytosolic tail of the receptor or, in part, by the nature of the ligand itself, as AGEs have been shown to generate reactive oxygen intermediates (38–40).

Since AGEs, though a diverse class of structures, represent the final and irreversible consequence of glycation and oxidation of proteins and lipids (1–8), elucidation of a major cellular acceptor site, such as RAGE, could provide insights into the pathogenesis of disorders in which they accumulate. Although future studies employing reagents which prevent AGE-RAGE interaction over longer periods of time will be



FIG. 3. Infusion of AGE albumin induces IL-6 mRNA as shown by PCR analysis. Mice were infused with either saline alone (0), native albumin (250 µg per animal) or AGE albumin (250 µg/animal) alone, or AGE albumin in the presence of anti-RAGE IgG or nonimmune IgG (40 µg per animal). Other animals received lipopolysaccharide (LPS, 100 µg per animal, i.v.). *B* shows Southern hybridization of the products obtained in *A* with ³²P-labeled oligonucleotide probe for murine IL-6. *C* shows PCR product obtained with β-actin-specific primers. Migration of DNA size (bp) markers (New England Biolabs) is shown at left.

required to dissect the possible contribution of RAGE to vascular dysfunction, the current experiments establish that AGEs in the intravascular space recognize RAGE on the vessel wall as a major cell-associated target.

This work was supported by grants from the U.S. Public Health Service and Fogarty International Center (AG00602, TW00118, HL42833, HL42507, and HL21006), the Juvenile Diabetes Foundation, the Council for Tobacco Research, and the American Heart Association, New York City Affiliate. D.S. completed this work during the tenure of a Genentech-American Heart Association Established Investigator Award.

- Ruderman, N., Williamson, J. & Brownlee, M. (1992) *Fed. Proc. Fed. Am. Soc. Exp. Biol.* 6, 2905–2914.
- Brownlee, M., Cerami, A. & Vlassara, H. (1988) *N. Engl. J. Med.* 318, 1315–1320.
- Sell, D. & Monnier, V. (1989) *J. Biol. Chem.* 264, 21597–21602.
- Dyer, D., Blackledge, J., Thorpe, S. & Baynes, J. (1991) *J. Biol. Chem.* 266, 11654–11650.
- Baynes, J. (1991) *Diabetes* 40, 405–412.
- McCance, D., Dyer, D., Dunn, J., Bailie, K., Thorpe, S., Baynes, J. & Lyons, T. (1993) *J. Clin. Invest.* 91, 2470–2478.
- Dyer, D., Dunn, J., Thorpe, S., Bailie, K., Lyons, T., McCance, D. & Baynes, J. (1993) *J. Clin. Invest.* 91, 2463–2469.
- Bucala, R., Makita, Z., Koschinsky, T., Cerami, A. & Vlassara, H. (1993) *Proc. Natl. Acad. Sci. USA* 90, 6434–6438.
- Yang, Z., Makita, J., Hori, Y., Brunelle, S., Cerami, A., Sehajpal, P., Suthanthiran, M. & Vlassara, H. (1991) *J. Exp. Med.* 174, 515–524.

- Schmidt, A.-M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., Wang, F., Pan, Y.-C., Tsang, T. C. & Stern, D. (1992) *J. Biol. Chem.* 267, 14987–14997.
- Schmidt, A.-M., Yan, S.-D., Brett, J., Mora, R., Nowyngrod, R. & Stern, D. (1993) *J. Clin. Invest.* 91, 2155–2168.
- Neper, M., Schmidt, A.-M., Brett, J., Yan, S.-D., Wang, F., Pan, Y.-C., Elliston, K., Stern, D. & Shaw, A. (1992) *J. Biol. Chem.* 267, 14998–15004.
- Brett, J., Schmidt, A.-M., Zou, Y.-S., Yan, S.-D., Weidman, E., Pinsky, D., Neper, M., Przysiecki, C., Shaw, A., Miglieli, A. & Stern, D. (1993) *Am. J. Pathol.* 143, 1699–1712.
- David, G. & Reisfeld, R. (1974) *Biochemistry* 13, 1014–1029.
- Horrisberger, M. & Rosset, J. (1977) *J. Histochem. Cytochem.* 25, 293–305.
- Slot, J. & Geuze, H. (1981) *J. Cell Biol.* 90, 533–536.
- Esposito, C., Gerlach, H., Brett, J., Stern, D. & Vlassara, H. (1989) *J. Exp. Med.* 170, 1387–1407.
- Choi, S., Fong, L., Kirven, M. & Cooper, A. (1991) *J. Clin. Invest.* 88, 1173–1181.
- Spady, D., Bilheimer, D. & Dietschy, J. (1983) *Proc. Natl. Acad. Sci. USA* 80, 3499–3503.
- Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- Chen, J., Border, P., Liao, J. & Kabat, E. A. (1992) *Mol. Immunol.* 29, 1121–1129.
- Laemmli, U. (1970) *Nature (London)* 227, 680–685.
- Predescu, D., Simionescu, M., Simionescu, N. & Palade, G. E. (1988) *J. Cell Biol.* 107, 1729–1738.
- Simionescu, M. (1988) in *Endothelial Cell Biology in Health and Disease*, eds. Simionescu, N. & Simionescu, M. (Plenum, New York), pp. 69–104.
- Ghinea, N., Fixman, A., Alexandru, D., Popov, D., Hasu, M., Ghitescu, L., Eskenasy, M., Simionescu, M. & Simionescu, N. (1988) *J. Cell Biol.* 107, 231–239.
- Ghitescu, L., Fixman, A., Simionescu, M. & Simionescu, N. (1986) *J. Cell Biol.* 102, 1304–1311.
- Schnitzer, J., Carley, W. & Palade, G. (1988) *Proc. Natl. Acad. Sci. USA* 85, 6773–6777.
- Vlassara, H., Brownlee, M., Manogue, K., Dinarello, C. & Passagian, A. (1988) *Science* 240, 1546–1548.
- Kirstein, M., Brett, J., Radoff, S., Stern, D. & Vlassara, H. (1990) *Proc. Natl. Acad. Sci. USA* 87, 9010–9014.
- Ganda, O. & Arkin, C. (1992) *Diabetes Care* 15, 1245–1250.
- Coller, B., Frank, R., Milton, R. & Gralnick, H. (1978) *Ann. Int. Med.* 88, 311–316.
- Fuller, J., Keen, H., Jarrett, R., Omer, T., Meade, T., Chakrabarti, R., North, W. & Stirling, Y. (1979) *Br. Med. J.* 2, 964–966.
- Kishimoto, T. & Harano, T. (1988) *Annu. Rev. Immunol.* 6, 485–512.
- Sehgal, P., Grieninger, G. & Tosata, G. (eds.) (1989) *Ann. N.Y. Acad. Sci.* 557, 1–583.
- Heinrich, P., Castell, J. & Andus, T. (1990) *Biochem. J.* 265, 621–636.
- Schmidt, A.-M., Anderson, M., Koga, S., Brett, J., Bierhaus, A., Nawrot, P., Nowyngrod, R. & Stern, D. (1992) *Blood* 80, (Suppl. 1), 403 (abstr.).
- Zhang, Y., Lin, J.-X. & Vilcek, J. (1990) *Mol. Cell. Biol.* 10, 3818–3823.
- Mullarkey, C., Edelstein, D. & Brownlee, M. (1990) *Biochem. Biophys. Res. Commun.* 173, 932–939.
- Sakurai, T., Sugioka, K. & Nakano, M. (1990) *Biochim. Biophys. Acta* 1043, 27–33.
- Yan, S.-D., Schmidt, A.-M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., Pinsky, D. & Stern, D. (1994) *J. Biol. Chem.* 269, 9889–9897.